Addex Therapeutics

Addex Therapeutics Gross Margin

The Gross Margin of Addex Therapeutics (ADXN) as of Oct 27, 2026 is 100.00 %. In the previous year, Gross Margin was 100.00 % — a change of 0.00% (lower).

Gross Margin

100.00 %

YoY

0.00%

Last updated:

Gross Margin of Addex Therapeutics is 2025 100.00 % . Gross Margin of Addex Therapeutics was 2024 100.00 % . It decreases by 0.00% lower compared to the previous year.

Addex Therapeutics's gross margin stands at 100.0%, broadly stable from 100.0% several years earlier.

The Addex Therapeutics Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
97.61 USD
Jan 1, 2019
91.67 USD
Jan 1, 2020
100.00 USD
Jan 1, 2021
100.00 USD
Jan 1, 2022
100.00 USD
Jan 1, 2023
100.00 USD
Jan 1, 2024
100.00 USD
Jan 1, 2025
100.00 USD
The Addex Therapeutics Gross Margin history
YEARGross MarginYoY
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %+9.08%
91.67 %-6.09%
97.61 %+3.79%
94.05 %-104.00%
-2,352.05 %-3,254.94%
74.55 %—
0.00-100.00%
-9.48 %+6.39%
-8.91 %-39.69%
-14.78 %-1,577.75%
1.00 %0.00%
1.00 %-24.27%
1.32 %+32.04%
1.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Addex Therapeutics Stock analysis

What does Addex Therapeutics do? Addex Therapeutics Ltd, based in Geneva, Switzerland, discovers and develops small-molecule pharmaceuticals targeting neurological disorders. The company focuses on G-protein coupled receptors and enzymes, with lead programs including Dipraglurant in Phase 1 for post-stroke/TBI recovery and Parkinson's disease, and ADX71149 in Phase 1 for undisclosed indications. It collaborates with Janssen Pharmaceuticals and Indivior PLC for GABAB PAM compounds addressing pain, anxiety, addiction, and other central nervous system conditions. Addex Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Addex Therapeutics stock

Gross Margin of Addex Therapeutics is 100.00 % in 2025.

Gross Margin of Addex Therapeutics changed from 100.00 % to 100.00 %, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Addex Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Addex Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Addex Therapeutics

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Addex Therapeutics